Zim Laboratories quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	94.2	71.8	+31.2%
EBITDA	2.5	4.3	−42.5%
EBITDA margin	2.6%	5.9%	−3.3 pts
Profit before tax	−5.6	−2.4	—
Net profit	−4.0	−1.9	—
EPS	−₹0.75	−₹0.38	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023

Expenses
	94.2	105	109	88.7	71.8	109	96.3	92.1	81.8	118	96.3	85.8
	1.0	6.2	1.7	2.0	1.5	1.7	1.8	1.3	1.0	1.5	1.1	1.4
	95.2	111	110	90.8	73.2	110	98.1	93.5	82.8	119	97.4	87.2
	43.8	49.7	43.2	43.5	27.6	48.6	39.9	35.5	31.0	53.5	51.5	41.0
	0.5	2.4	0.6	2.9	1.6	3.3	2.5	3.1	2.7	2.1	3.0	2.0
	−4.9	−4.9	4.8	−6.8	0.8	−3.6	−1.1	3.5	2.6	0.6	−10.3	−3.1
	19.2	17.4	15.6	16.3	14.6	16.3	14.5	15.5	14.5	14.7	13.2	12.8
	3.6	3.3	3.4	3.2	3.3	2.9	2.7	2.9	2.9	2.3	1.7	1.2
	5.4	5.1	5.0	5.0	4.9	5.3	4.9	5.0	4.9	3.9	3.9	4.1
	33.1	33.6	31.7	27.0	22.9	29.6	29.0	25.1	23.0	31.3	27.4	23.8
	101	106	104	91.1	75.7	102	92.4	90.5	81.6	108	90.4	81.8
	2.5	7.2	12.8	5.8	4.3	14.6	11.6	9.5	8.0	15.6	11.5	9.3
	−2.9	2.1	7.8	0.8	−0.6	9.3	6.7	4.5	3.1	11.7	7.6	5.2
Profit
	−5.6	4.9	6.0	−0.3	−2.4	8.1	5.7	3.0	1.2	11.0	7.0	5.4
	−5.6	4.9	6.0	−0.3	−2.4	8.1	5.7	3.0	1.2	11.0	7.0	5.4
	0.0	1.8	1.5	0.0	0.1	3.4	0.7	0.2	0.3	−1.3	1.3	0.8
	−1.6	−0.6	0.2	0.1	−0.6	−0.2	1.0	0.3	0.1	4.2	0.9	0.5
	−1.6	1.2	1.6	0.1	−0.6	3.2	1.7	0.6	0.3	2.9	2.2	1.3
	−4.0	3.7	4.4	−0.4	−1.9	4.9	4.0	2.4	0.9	8.1	4.8	4.1
	−4.0	3.7	4.4	−0.4	−1.9	4.9	4.0	2.4	0.9	8.1	4.8	4.1
	0.4	0.5	0.9	0.3	0.4	−0.4	0.3	0.2	−0.1	−0.1	−0.0	0.0
	−3.6	4.2	5.3	−0.1	−1.5	4.5	4.3	2.5	0.8	8.0	4.7	4.2
	−4.0	3.7	4.4	−0.4	−1.9	4.9	4.0	2.4	0.9	8.1	4.8	4.1
	−0.0	0.0	−0.0	0.0	0.0	−0.0	0.0	0.0	0.0	−0.0	0.0	0.0
Per share
	−₹0.75	₹0.76	₹0.90	−₹0.09	−₹0.38	₹1.01	₹0.82	₹0.49	₹0.18	₹1.66	₹0.98	₹0.85
	−₹0.75	₹0.76	₹0.90	−₹0.09	−₹0.38	₹1.01	₹0.82	₹0.49	₹0.18	₹1.66	₹0.98	₹0.85
Other comprehensive income — detail
	0.4	0.5	0.9	0.3	0.4	−0.4	—	—	—	—	—	—
	−0.0	0.4	−0.2	−0.2	−0.2	−0.4	−0.1	−0.1	−0.1	−0.1	−0.2	−0.2
	−0.0	0.1	−0.1	−0.1	−0.1	−0.1	—	—	—	—	—	—
	—	—	—	—	—	—	−0.0	−0.0	−0.0	−0.0	−0.0	−0.0
	0.4	0.2	1.0	0.5	0.6	−0.1	0.4	0.2	0.0	−0.0	0.1	0.1
	−3.6	4.2	5.3	0.3	−1.5	4.5	4.3	2.5	0.8	8.0	4.7	4.2
	−0.0	0.0	−0.0	−0.1	0.0	−0.0	0.0	0.0	0.0	−0.0	0.0	0.0
Per share — as-filed variants
	−₹0.75	₹0.76	₹0.90	−₹0.09	−₹0.38	₹1.01	₹0.82	₹0.49	₹0.18	₹1.66	₹0.98	₹0.85
	−₹0.75	₹0.76	₹0.90	−₹0.09	−₹0.38	₹1.01	₹0.82	₹0.49	₹0.18	₹1.66	₹0.98	₹0.85
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	54.7	58.1	60.1	49.1	41.7	60.5	55.1	50.0	45.6	61.7	52.1	45.9
	58.1%	55.2%	55.3%	55.3%	58.2%	55.6%	57.2%	54.3%	55.7%	52.3%	54.1%	53.5%
Adjusted (ex-exceptional items) — derived
	−5.6	4.9	6.0	−0.3	−2.4	8.1	5.7	3.0	1.2	11.0	7.0	5.4
	−4.0	3.7	4.4	−0.4	−1.9	4.9	4.0	2.4	0.9	8.1	4.8	4.1
	−₹0.75	₹0.76	₹0.90	−₹0.09	−₹0.38	₹1.01	₹0.82	₹0.49	₹0.18	₹1.66	₹0.98	₹0.85

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ZIMLAB₹141.26

Zim Laboratories Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersANUHPHR VALIANTLAB AHCL ALBERTDAVD WANBURY HALEOSLABS BAJAJHCARE THEMISMEDMcap ₹756 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	85.8	96.3	117.9	81.8	92.1	96.3	108.7	71.8	88.7	108.7	105.3	94.2
Other Income	1.4	1.1	1.5	1.0	1.3	1.8	1.7	1.5	2.0	1.7	6.2	1.0
Total Income	87.2	97.4	119.4	82.8	93.5	98.1	110.4	73.2	90.8	110.4	111.4	95.2
Expenses
+ Cost of Materials Consumed	41.0	51.5	53.5	31.0	35.5	39.9	48.6	27.6	43.5	43.2	49.7	43.8
+ Purchases of Stock-in-Trade	2.0	3.0	2.1	2.7	3.1	2.5	3.3	1.6	2.9	0.6	2.4	0.5
+ Changes in Inventories	-3.1	-10.3	0.6	2.6	3.5	-1.1	-3.6	0.8	-6.8	4.8	-4.9	-4.9
+ Employee Benefit Expense	12.8	13.2	14.7	14.5	15.5	14.5	16.3	14.6	16.3	15.6	17.4	19.2
+ Finance Costs	1.2	1.7	2.3	2.9	2.9	2.7	2.9	3.3	3.2	3.4	3.3	3.6
+ Depreciation & Amortisation	4.1	3.9	3.9	4.9	5.0	4.9	5.3	4.9	5.0	5.0	5.1	5.4
+ Other Expenses	23.8	27.4	31.3	23.0	25.1	29.0	29.6	22.9	27.0	31.7	33.6	33.1
Total Expenses	81.8	90.4	108.4	81.6	90.5	92.4	102.3	75.7	91.1	104.3	106.5	100.7
EBITDA	9.3	11.5	15.6	8.0	9.5	11.6	14.6	4.3	5.8	12.8	7.2	2.5
EBIT	5.2	7.6	11.7	3.1	4.5	6.7	9.3	-0.6	0.8	7.8	2.1	-2.9
Profit
PBT before Exceptional Items	5.4	7.0	11.0	1.2	3.0	5.7	8.1	-2.4	-0.3	6.0	4.9	-5.6
Pretax Income	5.4	7.0	11.0	1.2	3.0	5.7	8.1	-2.4	-0.3	6.0	4.9	-5.6
+ Current Tax	0.8	1.3	-1.3	0.3	0.2	0.7	3.4	0.1	0.0	1.5	1.8	0.0
+ Deferred Tax	0.5	0.9	4.2	0.1	0.3	1.0	-0.2	-0.6	0.1	0.2	-0.6	-1.6
Tax Expense	1.3	2.2	2.9	0.3	0.6	1.7	3.2	-0.6	0.1	1.6	1.2	-1.6
Net Income	4.1	4.8	8.1	0.9	2.4	4.0	4.9	-1.9	-0.4	4.4	3.7	-4.0
+ Net Income — Continuing Ops	4.1	4.8	8.1	0.9	2.4	4.0	4.9	-1.9	-0.4	4.4	3.7	-4.0
+ Other Comprehensive Income	0.0	-0.0	-0.1	-0.1	0.2	0.3	-0.4	0.4	0.3	0.9	0.5	0.4
Total Comprehensive Income	4.2	4.7	8.0	0.8	2.5	4.3	4.5	-1.5	-0.1	5.3	4.2	-3.6
Net Income to Common	4.1	4.8	8.1	0.9	2.4	4.0	4.9	-1.9	-0.4	4.4	3.7	-4.0
Minority Interest	0.0	0.0	-0.0	0.0	0.0	0.0	-0.0	0.0	0.0	-0.0	0.0	-0.0
Per Share
Basic EPS	0.85	0.98	1.66	0.18	0.49	0.82	1.01	-0.38	-0.09	0.90	0.76	-0.75
Diluted EPS	0.85	0.98	1.66	0.18	0.49	0.82	1.01	-0.38	-0.09	0.90	0.76	-0.75
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-0.4	0.4	0.3	0.9	0.5	0.4
+ Items NOT to be Reclassified to P&L	-0.2	-0.2	-0.1	-0.1	-0.1	-0.1	-0.4	-0.2	-0.2	-0.2	0.4	-0.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.1	-0.1	-0.1	-0.1	0.1	-0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.0	-0.0	-0.0	-0.0	-0.0	-0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	0.1	0.1	-0.0	0.0	0.2	0.4	-0.1	0.6	0.5	1.0	0.2	0.4
Comprehensive Income — Owners of Parent	4.2	4.7	8.0	0.8	2.5	4.3	4.5	-1.5	0.3	5.3	4.2	-3.6
Comprehensive Income — Non-controlling Interests	0.0	0.0	-0.0	0.0	0.0	0.0	-0.0	0.0	-0.1	-0.0	0.0	-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.85	0.98	1.66	0.18	0.49	0.82	1.01	-0.38	-0.09	0.90	0.76	-0.75
Diluted EPS — Continuing Operations	0.85	0.98	1.66	0.18	0.49	0.82	1.01	-0.38	-0.09	0.90	0.76	-0.75
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	45.9	52.1	61.7	45.6	50.0	55.1	60.5	41.7	49.1	60.1	58.1	54.7
Gross Margin %	53.49	54.08	52.33	55.72	54.30	57.17	55.62	58.18	55.31	55.28	55.24	58.09
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	5.4	7.0	11.0	1.2	3.0	5.7	8.1	-2.4	-0.3	6.0	4.9	-5.6
Net Income Adj (tax-effected)	4.1	4.8	8.1	0.9	2.4	4.0	4.9	-1.9	-0.4	4.4	3.7	-4.0
EPS Adj	0.85	0.98	1.66	0.18	0.49	0.82	1.01	-0.38	-0.09	0.90	0.76	-0.75
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Filed Debt Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.47	0.47	0.44	0.42	0.50
Filed Dscr	2.00	2.00	3.00	1.00	2.00	2.00	1.88	0.78	0.91	1.42	1.33	0.53
Filed Iscr	5.00	5.00	6.00	1.00	2.00	3.00	3.79	0.26	0.89	2.76	2.49	-0.53
Paid Up Equity Capital	48.7	48.7	48.7	48.7	48.7	48.7	48.7	48.7	48.7	48.7	53.5	53.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Zim Laboratories Q2 FY27 results date

Zim Laboratories (NSE: ZIMLAB) will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, according to the board-meeting notice it filed on 28 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net loss was ₹4 crore, wider than the loss of ₹1.9 crore in Q1 FY26 and against a profit of ₹3.7 crore in Q4 FY26. Revenue from operations was ₹94.2 crore, up 31.2% year on year and down 10.5% from the previous quarter.

Board-meeting notice filed: 28 October 2026
Q2 FY26 results (a year earlier): 12 November 2025
Q1 FY27 results (the latest): 6 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 4 November 2026Wednesday · notice filed 28 Oct
Q1 FY27 net loss: −₹4 Crloss ₹1.9 Cr in Q1 FY26profit ₹3.7 Cr in Q4 FY26
Q1 FY27 revenue: ₹94.2 Cr+31.2% vs Q1 FY26−10.5% vs Q4 FY26
Q1 FY27 operating margin: −3.1%−2.3 pts vs Q1 FY26−5.1 pts vs Q4 FY26
Q2 FY26 net loss (a year earlier): −₹42 lakhRevenue ₹88.7 Cr
Q1 FY27 EPS (basic): −₹0.75

Questions

When will Zim Laboratories announce its Q2 FY27 results?

On 4 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 28 October 2026). Last year it reported Q2 FY26 on 12 November 2025.

What were Zim Laboratories' Q1 FY27 results?

Consolidated net loss was ₹4 crore, wider than the loss of ₹1.9 crore in Q1 FY26 and against a profit of ₹3.7 crore in Q4 FY26. Revenue from operations was ₹94.2 crore, up 31.2% year on year and down 10.5% from the previous quarter.

What was Zim Laboratories' net profit in FY26?

Consolidated net profit was ₹5.8 crore in FY26 (April 2025–March 2026), down 52.0% from ₹12.2 crore in FY25. It was ₹17.2 crore in FY24 and ₹24.4 crore in FY23: down 76.1% over three years, an average fall of 37.9% a year.

What will Zim Laboratories' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net loss was ₹42 lakh and revenue from operations ₹88.7 crore. The latest quarter, Q1 FY27, had a net loss of ₹4 crore and revenue of ₹94.2 crore.

How has Zim Laboratories' profit changed over the last four quarters?

Net profit by quarter: a loss of ₹42 lakh in Q2 FY26, a profit of ₹4.4 crore in Q3 FY26, a profit of ₹3.7 crore in Q4 FY26 and a loss of ₹4 crore in Q1 FY27. That is a combined profit of ₹3.7 crore over the four quarters, down 60.6% from ₹9.4 crore in the four quarters before. Revenue from operations: ₹88.7 crore, ₹109 crore, ₹105 crore and ₹94.2 crore.

What was Zim Laboratories' revenue in FY26?

Revenue from operations was ₹374 crore in FY26 (April 2025–March 2026), down 1.2% from ₹379 crore in FY25. It was ₹367 crore in FY24 and ₹399 crore in FY23: down 6.1% over three years, an average fall of 2.1% a year.

Where do these Zim Laboratories figures come from?

From Zim Laboratories' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.